Research programme: ephrin-targeted cancer therapeutics - MedImmune

Drug Profile

Research programme: ephrin-targeted cancer therapeutics - MedImmune

Alternative Names: EA5; MEDI-543; MEDI-548; MEDI-549

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Purdue Research Foundation
  • Developer MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Eph family receptor antagonists; EphA2 receptor antagonists; EphB4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 14 Dec 2008 Pharmacodynamics data from a preclinical study in breast cancer presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS-2008)
  • 15 Aug 2008 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top